Skip to content

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Rogers Corporation logo
Rogers CorporationROG
+0.1×
Merck & Co. logo
Merck & Co.MRK
1.3×-0.1×
Gilead Sciences logo
Gilead SciencesGILD
+0.6×
Nuvation Bio logo
Nuvation BioNUVB
7.4×-1.6×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
14×-0.4×

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+385%
Enterprise value$1.42B+982%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×

Where this comes from

Calculated from Inhibrx Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s current ratio?
Inhibrx Biosciences, Inc. (INBX) reported current ratio of 6.5× in Q1 2026.
How has Inhibrx Biosciences, Inc.'s current ratio changed year-over-year?
Inhibrx Biosciences, Inc.'s current ratio increased by 26.3% year-over-year, from 5.1× to 6.5×.
What is the long-term trend for Inhibrx Biosciences, Inc.'s current ratio?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s current ratio has grown at a -13.4% compound annual growth rate (CAGR), from 5.2× to 3.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.